Drug Trial Radar · NCT05292911
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Mar 9, 2022
Primary completion
Oct 31, 2022
Study completion Oct 31, 2022
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
Conditions
- Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801Drug
Injected subcutaneously (SC)
PlaceboOther
Injected subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Day 110
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Catalina Research Institute
Montclair, California
Clinical Trials Research
Sacramento, California
Panax Clinical Research
Miami Lakes, Florida
Covenant Research and Clinics
Sarasota, Florida
Headlands Research Sarasota
Sarasota, Florida
Wake Research CRCN
Las Vegas, Nevada
Accelemed Research Institute
Austin, Texas
Pinnacle Research
Austin, Texas
South Texas Research Institute
Brownsville, Texas
South Texas Research Institute
Edinburg, Texas
Diagnostics Research Group
San Antonio, Texas
Pinnacle Research
San Antonio, Texas
Cognitive Clinical Trials
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.